Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 8Phase 2/3 3Phase NA 2Phase 1/2 2Phase 1 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other 1Genitourinary 1Breast 1

Conditions

Sexual Dysfunctions, Psychological 1Prostatic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 83Cyclophosphamide 55Specimen Handling 54Carboplatin 53fludarabine 44Nivolumab 43Magnetic Resonance Spectroscopy 43Gemcitabine 41Biopsy 40venetoclax 33Bevacizumab 33Dexamethasone 31Paclitaxel 29Pemetrexed 27Injections 27Cisplatin 27Docetaxel 26Azacitidine 22atezolizumab 21Rituximab 21Oxaliplatin 21Capecitabine 21Lenalidomide 20Ipilimumab 20Temozolomide 19Fulvestrant 19Cetuximab 19abemaciclib 18Fluorouracil 18Cytarabine 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leuprolide × 90 days × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT04194554 2026-05-01

ASCLEPIuS

University of Michigan Rogel Cancer Center

Phase 1/2 Active not recruiting
102 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡